- Home
- BRNX vs VBIO Comparison
BRNX vs VBIO Comparison
Compare BRNX & VBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BRNX | VBIO |
|---|---|---|
| Founded | 2012 | 2016 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5M | 1.3M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BRNX | VBIO |
|---|---|---|
| Price | $0.42 | $0.48 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 67.2K | ★ 312.7K |
| Earning Date | 09-09-2026 | 11-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $780,000.00 |
| Revenue This Year | $35,081.65 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.41 | $0.12 |
| 52 Week High | $10.36 | $812.50 |
Technical Indicators
Market Signals| Indicator | BRNX | VBIO |
|---|---|---|
| Relative Strength Index (RSI) | 25.73 | 21.34 |
| Support Level | $0.41 | $0.12 |
| Resistance Level | $2.49 | $4.39 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | 0.03 | 1.00 |
| Stochastic Oscillator | 1.17 | 3.62 |
Price Performance
Historical ComparisonAbout BRNX BrenX Ltd. Ordinary Shares
BrenX Ltd is reshaping industrial energy to make it cleaner, more reliable, and lower cost. Building on its proprietary bGen thermal energy storage technology, which converts electricity and recovered heat into dispatchable energy, BrenX develops, owns, operates, and optimizes energy assets that serve industrial customers and data centers. From local generation and storage to grid connectivity and intelligent energy management, BrenX brings together technologies and infrastructure to create complete energy platforms around customer needs, with flexible energy assets designed to meet growing energy demand.
About VBIO Valion Bio Inc. Common Stock
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.